Posted by Michael Wonder on 16 May 2020
Cancer patients demand Ono, BMS, MSD share immunotherapy cost
15 May 2020 - Immunotherapies Optivo, marketed by Ono Pharma Korea and BMS Korea, and Keytruda by MSD Korea, have recently failed to obtain reimbursement for expanded indication, as the government said such reimbursement would increase the national health insurance spending.
Unhappy about the reimbursement failure, cancer patient groups held a rally to demand the drugmakers share the cost of expensive immunotherapies.
The Korea Alliance of Patients Organization, composed of patients with leukemia, gastrointestinal stromal tumour, renal cancer, congenital heart defect, psoriasis, and type 1 diabetes, held a news conference in front of Ono Pharma Korea in southern Seoul, on Thursday.
